Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Ramucirumab (CYRAMZA®)
DRUG
2 trials
Sponsors
Sanofi
, Elevation Oncology
Conditions
Adenocarcinoma Gastric
Digestive System Neoplasm
Gastrointestinal Neoplasms
Gastrooesophageal Cancer
Neoplasms
Neoplasms by Site
Stomach Neoplasm
Phase 1
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Terminated
NCT05980416
Elevation Oncology
Digestive System Neoplasm, Gastrointestinal Neoplasms, Neoplasms +2
Start: 2023-08-10
End: 2025-06-02
Updated: 2025-11-14
Phase 2
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer
Terminated
NCT05071053
Sanofi
Adenocarcinoma Gastric, Gastrooesophageal Cancer
Start: 2021-11-16
End: 2024-11-05
Updated: 2025-08-22
Related Papers
A phase I study of EO-3021 in adult patients with solid tumors likely to express CLDN18.2.
Journal of Clinical Oncology
2024-01-20
1 citations
Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
Cancer Research Communications
2023-08-03
11 citations